---
title: "Bloomberg: A Nasal Gel to Help Fight Superbugs Stays in Limbo"
description: A brief article about antimicrobial developers and the market challenges they face.
---

 July 21, 2025

[In the News](https://www.amractionfund.com/blog/tag/in-the-news)

# Bloomberg: A Nasal Gel to Help Fight Superbugs Stays in Limbo

AMR Action Fund CEO Henry Skinner was quoted by Bloomberg in a piece about Destiny Pharma and its struggles to raise capital for late-stage clinical trials of its antimicrobial asset.

When a company goes bankrupt or into administration, the worst-case scenario for an asset-in-development is that it “goes into the trash bin of history,” says Henry Skinner, CEO of the AMR Action Fund, a venture capital fund that invests in antimicrobial therapeutics. Another option is that it “gets sold for pennies — if there’s a buyer for it.”

Read the [full article here](https://www.bloomberg.com/news/newsletters/2025-07-21/a-nasal-gel-to-help-fight-superbugs-stays-in-limbo?embedded-checkout=true).

![](https://www.amractionfund.com/hubfs/raw_assets/public/amr-action-fund/images/contact-bg-img.png)

## Connect With Us

[ Contact ](https://www.amractionfund.com/blog/bloomberg-a-nasal-gel-to-help-fight-superbugs-stays-in-limbo#)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "admin",
    "url" : "https://www.amractionfund.com/blog/author/admin"
  },
  "dateModified" : "2025-07-21T12:48:17.323Z",
  "datePublished" : "2025-07-21T09:30:00.000Z",
  "headline" : "Bloomberg: A Nasal Gel to Help Fight Superbugs Stays in Limbo",
  "mainEntityOfPage" : {
    "@id" : "https://www.amractionfund.com/blog/bloomberg-a-nasal-gel-to-help-fight-superbugs-stays-in-limbo",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject"
    }
  }
}
```